Schlegel L, Sissia G, Fremaux A, Geslin P
Centre National de Référence des Pneumocoques, Centre Hospitalier Intercommunal, Créteil, France.
J Antimicrob Chemother. 1997 Jan;39(1):95-8. doi: 10.1093/jac/39.1.95.
Streptococcus pneumoniae has developed resistance to almost every antibacterial agent used in clinical practice, including the most active beta-lactams. This has led to the proposed use of drug combinations. The aim of this study was to determine the efficacy of combinations of beta-lactam agents (cefotaxime or imipenem) with aminoglycosides (gentamicin, netilmicin or amikacin) against pneumococci showing high-level resistance to penicillin and streptomycin and/or kanamycin. All tested combinations were bactericidal and synergic despite the weak concentrations of antibiotics used. Our results suggest that combinations of beta-lactam agents with aminoglycosides may be useful for treating infections by penicillin-resistant pneumococci located outside the central nervous system.
肺炎链球菌已对临床实践中使用的几乎每种抗菌药物产生耐药性，包括活性最强的β-内酰胺类药物。这导致了联合用药方案的提出。本研究的目的是确定β-内酰胺类药物（头孢噻肟或亚胺培南）与氨基糖苷类药物（庆大霉素、奈替米星或阿米卡星）联合使用对显示出对青霉素和链霉素及/或卡那霉素高度耐药的肺炎球菌的疗效。尽管使用的抗生素浓度较低，但所有测试的联合用药均具有杀菌作用且具有协同作用。我们的结果表明，β-内酰胺类药物与氨基糖苷类药物联合使用可能有助于治疗中枢神经系统以外部位的耐青霉素肺炎球菌感染。
